Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.

@article{Singh2017OverviewOH,
  title={Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies.},
  author={Nathan Singh and Alison W. Loren},
  journal={Clinics in chest medicine},
  year={2017},
  volume={38 4},
  pages={
          575-593
        }
}
Allogeneic hematopoietic cell transplantation offers the best chance for cure in many hematologic malignancies. Key decisions include patient selection, donor and graft source, conditioning regimen, and graft-versus-host disease (GVHD) prophylaxis. Transplant is risky; only one-third survive long term. Complications include relapse, GVHD, infection, and end-organ dysfunction. Expanding indications for transplantation, advancing upper age limits, and improvements in patient care have resulted in… CONTINUE READING
BETA

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 149 REFERENCES

High HLA-DP expression and graft-versus-host disease.

  • The Lancet. Oncology
  • 2015
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

  • The New England journal of medicine
  • 2016
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Reduced-intensity conditioned allogeneic SCT in adults with AML

  • Bone Marrow Transplantation
  • 2015
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…